- Business Wire•12 days agoAeterna Zentaris and Specialised Therapeutics Asia Sign Exclusive License Agreement for the Potential Marketing of Zoptrex™ in Australia and New Zealand
Aeterna Zentaris Inc. and Specialised Therapeutics Asia today announced the signing of an exclusive license agreement for the Company’s lead investigational anti-cancer compound, Zoptrex™ , for the territories of Australia and New Zealand .
- Business Wire•last month
Aeterna Zentaris Inc. today announced that the remaining 8,064 Series B Common Share Purchase Warrants issued in connection with the Company’s March 2015 financing expired on September 12, 2016 without being exercised.
Aeterna Zentaris Inc. (AEZ.TO)
Toronto - Toronto Delayed Price. Currency in CAD
|Day's Range||6.36 - 6.92|
|52wk Range||3.77 - 20.93|
|1y Target Est||N/A|
|P/E Ratio (ttm)||-1.34|
|Avg Vol (3m)||24,669|
|Dividend & Yield||0.00 (0.00%)|